Accessibility Menu
Aprea Therapeutics logo

Aprea Therapeutics

(NASDAQ) APRE

Current Price$0.68
Market Cap$8.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-95%
5 Year-99%
1 Year-58%
1 Month-5%
Aprea Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.692026-07-16
Aprea Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.22%USD 0.732026-07-09
1 month-5.39%USD 0.732026-06-16
3 month-31%USD 1.002026-04-17
Year to date-19.11%USD 0.852025-12-31
1 year-58.43%USD 1.662025-07-16
3 year-78.6%USD 3.222023-07-17
5 year-99.32%USD 100.802021-07-16
Since inception-94.9%USD 13.542022-05-17

Aprea Therapeutics Financials at a Glance

Market Cap

$8.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$118.11K

Net Income (TTM)

-$11.95M

EPS (TTM)

-$1.54

P/E Ratio

-0.45

Dividend

$0.00

Beta (Volatility)

-0.80 (Low)

Price

$0.68

Volume

100

Open

$0.68

Previous Close

$0.68

Daily Range

$0.68 - $0.68

52-Week Range

$0.55 - $2.22

Estimated Earnings Date

Aug 11, 2026

APRE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aprea Therapeutics

Aprea develops medicines for people with advanced cancers. Its main drugs aim to target cancer cells while sparing healthy ones. These treatments are designed for patients with specific genetic mutations in their tumors.

Products and Services

  • ATRN-119 (ATR inhibitor): Oral drug in early trials for advanced solid tumors; 0% of revenue (no product sales).
  • APR-1051 (WEE1 inhibitor): Oral drug in Phase 1 trials for tumors with certain genetic changes; 0% of revenue.
  • ATRN-Backup: Preclinical drug candidate, not yet in human trials; 0% of revenue.
  • ATRN-W1051: Preclinical drug targeting anti-tumor activity; 0% of revenue.
  • APR-1602 (DYRK1A/B inhibitor): Early-stage drug for future cancer studies; 0% of revenue.

Growth and Expansion

  • Launched Phase 1 trial for APR-1051 in 2025, expanding clinical pipeline.
  • Completed Phase 1/2a study for ATRN-119 in 2025, shifting focus to combination therapies.
  • Added APR-1602 to pipeline in 2025, with plans for further studies in 2026.
  • Raised $5.6 million in January 2026 through private placement to extend cash runway.
  • Maintains all global rights to its drug candidates, allowing future partnerships.

What Makes Aprea Stand Out

Aprea focuses on precision cancer drugs that target tumor DNA repair weaknesses. Its approach aims to kill cancer cells with specific mutations, reducing harm to healthy cells. The company develops all main drug candidates internally and holds patents worldwide.

Five Things You Need to Know

  • Revenue was $1,848 in Q3 2025, down 99.5% from Q3 2024.
  • Net loss was $3,581 in Q3 2025, improved from $2 million in Q3 2024.
  • Cash and equivalents were $9 million in Q3 2025, down 42.3% year-over-year.
  • Operating expenses were $13.5 million in FY2025, down from $15.8 million in FY2024.

Bottom Line

Aprea remains focused on early-stage cancer drug development with a small team and limited revenue. The company faces ongoing financial challenges but continues to advance its clinical pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Oren Gilad, PhD

Website

www.aprea.com

Headquarters

Boston, PA 02116, US

APRE Financials

Key Financial Metrics (TTM)

Gross Margin

-1523.59%

Operating Margin

-10649.87%

Net Income Margin

-10121.69%

Return on Equity

-59.54%

Return on Capital

-106.37%

Return on Assets

-24.85%

Earnings Yield

-2.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.38M

Volume

100

Avg. Volume

160.63K

Financials (TTM)

Gross Profit

-$1.80M

Operating Income

-$12.58M

EBITDA

-$11.93M

Operating Cash Flow

-$12.22M

Capital Expenditure

$0.00

Free Cash Flow

-$12.22M

Cash & ST Invst.

$46.47M

Total Debt

$0.00

Aprea Therapeutics Performance Analysis

Aprea Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 583,231N/A
20242024-12-31USD 1,502,581157.6%
20252025-12-31USD 285,759-81.0%
Aprea Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-27.3%
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
Aprea Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,359.793798.1%
20232023-12-31USD -3.95-99.7%
20242024-12-31USD -2.35-40.4%
20252025-12-31USD -1.93-18.1%
Aprea Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3019.7%
Q32025-09-3011.3%
Q42025-12-3131.9%
Q12026-03-31-34.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$5.43K

+99.8%

Gross Margin

0.00%

N/A

Market Cap

$8.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.07M

N/A

Employees

8

N/A

Net Income

-$3.29M

+16.4%

EBITDA

-$3.28M

+16.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$46.47M

+141.1%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-24.85%

N/A

Return on Invested Capital

-29.38%

N/A

Free Cash Flow

-$2.76M

+24.1%

Operating Cash Flow

-$2.76M

+24.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RNAZTransCode Therapeutics, Inc.
$8.27-4.89%
APVOAptevo Therapeutics Inc.
$4.50-1.53%
KPRXKiora Pharmaceuticals, Inc.
$2.55+2.82%
BCDABioCardia, Inc.
$0.86-2.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NOKNokia
$10.38-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.74-0.05%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.89+0.05%

Questions About APRE

What is the current price of Aprea Therapeutics?

Aprea Therapeutics is trading at $0.68 per share.

What is the 52-week range for Aprea Therapeutics?

Over the past 52 weeks, Aprea Therapeutics has traded between $0.55 and $2.22.

How much debt does Aprea Therapeutics have?

As of the most recent reporting period, Aprea Therapeutics reported total debt of $0.00.

How much cash does Aprea Therapeutics have on hand?

Aprea Therapeutics reported $46.47M in cash and cash equivalents in its most recent financial results.

What is Aprea Therapeutics’s dividend yield?

Aprea Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services